Table 1.

Comparison of baseline characteristics between patients of non-segmented and segmented gallbladder groups

Variables		Non-segmented GB, n = 205	Segmented GB, n = 63	P value
Age in year		51.8 ± 13.6	51.1 ± 11.3	0.664
Male		87 (42.4%)	29 (46.0%)	0.72
Atypical symptoms		52 (25.4%)	9 (14.3%)	0.085
Biliary colic pain		50 (24.4%)	10 (15.9%)	0.171
Laboratory findings
	ALP in IU/L	67.6 ± 24.6	68.0 ± 20.5	0.911
	GGT in IU/L	37.1 ± 54.9	33.1 ± 28.4	0.58
	AST in IU/L	24.2 ± 8.7	26.3 ± 14.7	0.163
	ALT in IU/L	23.5 ± 12.7	26.3 ± 15.4	0.148
	Total bilirubin in mg/dL	1.05 ± 2.60	0.86 ± 0.41	0.583
	Direct bilirubin in mg/dL	0.31 ± 0.87	0.25 ± 0.12	0.59
	CEA in ng/mL	1.58 ± 1.31	1.35 ± 0.83	0.31
Radiologic findings
	GB stone	110 (53.7%)	37 (58.7%)	0.563
	GB sludge	7 (3.4%)	2 (3.2%)	0.999
	GB polyp	14 (6.8%)	8 (12.7%)	0.186
	Adenomyomatosis	12 (5.9%)	18 (28.6%)	< 0.001
	Chronic cholecystitis	107 (52.2%)	45 (71.4%)	0.009
Reported GBEF, %		67.40 ± 21.78	70.05 ± 22.97	0.405
Cholecystectomy		73 (35.6%)	45 (71.4%)	< 0.001
Pathology1
	Adenomyomatosis	3 (4.1%)	5 (11.1%)	0.257
	Chronic cholecystitis	68 (93.2%)	41 (91.1%)	0.73
	Cholesterol polyp	16 (21.9%)	7 (15.6%)	0.478

¹Duplicate test results.

Data were expressed as n (percentage) or mean ± SD. Comparisons were performed using the Student’s t-test, Pearson’s chi-squared test, and Fisher’s exact test. ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; GB: Gallbladder; GBEF: Gallbladder ejection fraction; GGT: Gamma (γ)-gamma-glutamyl transferase.